{{위키데이터 속성 추적}}
{{Infobox drug
| Watchedfields = changed
| verifiedrevid = 458612013
| drug_name = 
| INN = 
| type = <!-- empty -->
| image = Celecoxib2DACS.svg
| width = 220
| alt = Skeletal formula of celecoxib
| image2 = Celecoxib-3D-spacefill.png
| width2 = 
| alt2 = Space-filling model of the celecoxib molecule
| caption =

<!-- Clinical data -->
| pronounce = {{IPAc-en|s|ɛ|l|ɪ|ˈ|k|ɒ|k|s|ɪ|b}} {{respell|SEL|i|KOK|sib}}
| tradename = Celebrex, Onsenal, Elyxyb, others
| Drugs.com = {{drugs.com|monograph|celecoxib}}
| MedlinePlus = a699022
| licence_CA = <!-- Health Canada may use generic or brand name (generic name preferred) -->
| licence_EU = <!-- EMA uses INN (or special INN_EMA) -->
| DailyMedID = Celecoxib
| licence_US = Celebrex
| pregnancy_AU = B3
| pregnancy_AU_comment =<ref name="Drugs.com pregnancy">{{웹 인용| title=Celecoxib (Celebrex) Use During Pregnancy | website=Drugs.com | date=4 May 2020 | url=https://www.drugs.com/pregnancy/celecoxib.html | access-date=5 May 2020}}</ref>
| pregnancy_US = C up to 30 weeks; D after 29 weeks
| pregnancy_US_comment =<ref name="Drugs.com pregnancy" />
| pregnancy_category= 
| dependency_liability = 
| addiction_liability = 
| routes_of_administration = [[Oral administration|By mouth]]
| class = [[COX-2 inhibitor|Cyclooxygenase-2 (COX-2) inhibitor]]
| ATCvet = 
| ATC_prefix = L01
| ATC_suffix = XX33
| ATC_supplemental = {{ATC|M01|AH01}}

<!-- Legal status -->
| legal_AU = S4
| legal_AU_comment = 
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR_comment = 
| legal_CA = Rx-only
| legal_CA_comment = 
| legal_DE = <!-- Anlage I, II, III or Unscheduled-->
| legal_DE_comment = 
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment = 
| legal_UK = POM
| legal_UK_comment =<ref>{{웹 인용| title=Celebrex 100mg capsule - Summary of Product Characteristics (SmPC) | website=(emc) | date=13 January 2020 | url=https://www.medicines.org.uk/emc/product/5533/smpc | access-date=5 May 2020}}</ref>
| legal_US = Rx-only
| legal_US_comment =<ref name="Celebrex FDA label">{{웹 인용| title=Celebrex- celecoxib capsule | website=DailyMed | date=31 May 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226 | access-date=5 May 2020 | archive-date=24 February 2021 | archive-url=https://web.archive.org/web/20210224181140/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226 | url-status=live }}</ref>
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_UN_comment = 
| legal_status = Rx-only

<!-- Pharmacokinetic data -->
| bioavailability = Unknown<ref name=drugs>{{저널 인용| vauthors = McCormack PL | title = Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis | journal = Drugs | volume = 71 | issue = 18 | pages = 2457–89 | date = December 2011 | pmid = 22141388 | doi = 10.2165/11208240-000000000-00000 }}</ref>
| protein_bound = 97% (mainly to [[serum albumin]])<ref name = drugs/>
| metabolism = Liver (mainly [[CYP2C9]])<ref name = drugs/>
| metabolites = 
| onset = 
| elimination_half-life = 7.8 hours; 11 hours (mild hepatic impairment); 13 hours (moderate-severe hepatic impairment)<ref name = drugs/>
| duration_of_action = 
| excretion = Faeces (57%), urine (27%)<ref name = drugs/>

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 169590-42-5
| CAS_supplemental = 
| PubChem = 2662
| IUPHAR_ligand = 2892
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00482
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2562
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = JCX84Q7J1L
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00567
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 41423
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 118
| NIAID_ChemDB = 
| PDB_ligand = CEL
| synonyms =

<!-- Chemical and physical data -->
| IUPAC_name = 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
| C=17 | H=14 | F=3 | N=3 | O=2 | S=1
| molecular_weight = 381.373
| SMILES = O=S(=O)(c3ccc(n1nc(cc1c2ccc(cc2)C)C(F)(F)F)cc3)N
| Jmol = 
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
| StdInChI_comment = 
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RZEKVGVHFLEQIL-UHFFFAOYSA-N
| density = 
| density_notes = 
| melting_point = 
| melting_high = 
| melting_notes = 
| boiling_point = 
| boiling_notes = 
| solubility = 
| sol_units = 
| specific_rotation = 
}}
'''세레콕시브'''(Celecoxib)는 COX-2 선택적 [[비스테로이드 항염증제]](NSAID)이다. 상품명 '''쎄레브렉스'''(Celebrex)로 알려져 있기도 하다. 세레콕시브는 [[골관절염]], [[류마티스 관절염]], [[강직성 척주염]], 성인의 [[급성 통증]], [[월경통]], 2세 이상의 [[소아기특발성관절염]] 환자의 [[통증]] 및 [[염증]] 조절을 위하여 사용된다.

[[대한민국]] [[식품의약품안전처]]에서는 골관절염(퇴행관절염)의 증상이나 징후의 완화, 류마티스관절염의 증상이나 징후의 완화, 강직척추염의 증상 및 징후의 완화,성인의 급성 통증 완화(수술후, 발치후 진통), 원발월경통의 증상 조절을 위한 사용이 허가되어 있다.

세레콕시브 투약 이후 주된 부작용으로는 [[심혈관계질환]], [[위장출혈|상부 위장관 출혈]] 등이 있다. 2013년 발표된 세레콕시브와 기타 [[비스테로이드 항염증제]]간의 메타분석 논문에 따르면 세레콕시브의 심혈관계질환 유발의 [[위험비]]는 [[나프록센]]의 1.49배, [[디클로페낙]]의 0.97배, [[이부프로펜]]의 0.92배로 나타났으며, 상부위장관출혈의 위험비는 나프록센의 0.37배, 디클로페낙의 0.94배, 이부프로펜의 0.40배로 조사되었다.<ref>{{저널 인용|제목=Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials|저널=The Lancet|url=https://doi.org/10.1016/S0140-6736(13)60900-9|날짜=2013-08|권=382|호=9894|쪽=769–779|doi=10.1016/s0140-6736(13)60900-9|issn=0140-6736|pmc=3778977|pmid=23726390}}</ref>

== 각주 ==
<references />

[[분류:비스테로이드 항염증제]]
[[분류:화이자의 제품]]
[[분류:항암제]]
[[분류:CYP2D6 억제제]]